BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/5/2025 11:28:04 AM | Browse: 14 | Download: 37
 |
Received |
|
2025-06-09 10:20 |
|
Peer-Review Started |
|
2025-06-09 10:21 |
|
First Decision by Editorial Office Director |
|
2025-07-03 10:42 |
|
Return for Revision |
|
2025-07-03 10:42 |
|
Revised |
|
2025-07-24 18:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-10-30 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-30 10:12 |
|
Articles in Press |
|
2025-10-30 10:12 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-24 01:21 |
|
Publish the Manuscript Online |
|
2025-12-05 11:28 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Minireviews |
| Article Title |
Emerging role of Janus kinase inhibitors in ulcerative colitis management
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Muhammad Umar Ahsan, Syeda Laiba Sajid, Rahul Balach, Muhammad Daniyal, Noor Ul Ain and Muhammad Mudasir |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Muhammad Umar Ahsan, Researcher, Department of medicine, D.G. Khan Medical College, D.G.Khan Medical College, Dera Ghazi Khan, Punjab, Pakistan., Dera Ghazi Khan 32200, Punjab, Pakistan. umarahsan219@gmail.com |
| Key Words |
Ulcerative colitis; Janus Kinase inhibitors; Tofacitinib; Upadacitinib; Small molecules; Inflammatory bowel disease; Targeted therapy |
| Core Tip |
Ulcerative colitis (UC) is a difficult condition that often doesn’t respond well to standard treatments. This review looks at the growing role of Janus kinase (JAK) inhibitors, a type of oral medication that targets specific pathways involved in inflammation. While older drugs like tofacitinib showed promise, they raised some safety concerns. Newer options, such as upadacitinib and filgotinib, appear to offer better safety alongside strong clinical results. Overall, this review highlights how these treatments could help people with moderate-to-severe UC who need more effective and reliable options to manage their condition. |
| Publish Date |
2025-12-05 11:28 |
| Citation |
Ahsan MU, Sajid SL, Balach R, Daniyal M, Ain NU, Mudasir M. Emerging role of Janus kinase inhibitors in ulcerative colitis management. World J Gastrointest Pharmacol Ther 2025; 16(4): 110472 |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i4/110472.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i4.110472 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
